Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01596127 · ClinicalTrials.gov registry record · Phase 1
Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
NCT01596127: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT01596127 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01596127, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn about the safety and effectiveness of rituximab given by spinal tap in patients with lymphoid malignancies involving the central nervous system. A spinal tap (also called a lumbar puncture) is when fluid surrounding the spinal cord is collected by inserting a needle into the lower back. The affected area is numbed with local anesthetic during the procedure. It will also be used to give chemotherapy in this study. Rituximab is designed to bind to a protein, called CD20, that is on the surface of the leukemia cells. This may cause the leukemia cells to die.
Interventions
- DRUG Intrathecal Rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2013-01-24 |
| Est. Completion | 2017-03-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01596127
The ClinicalTrials.gov registry entry for NCT01596127 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intrathecal Rituximab is the first listed.
NCT01596127 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01596127 about?
NCT01596127 is a clinical study titled "Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System". The goal of this clinical research study is to learn about the safety and effectiveness of rituximab given by spinal tap in patients with lymphoid malignancies involving the central nervous system. A spinal tap (also called a lumbar puncture) is when fluid surrounding the spinal cord is collected b...
What is the current status of trial NCT01596127?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2013-01-24. Estimated completion is 2017-03-23.
What interventions are being tested in trial NCT01596127?
The interventions under investigation include: Intrathecal Rituximab (DRUG).
Who is sponsoring clinical trial NCT01596127?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.